Healthier Populations, Everywhere

We are value driven, not just in the sense of the values we adhere to, but also in the solutions we offer. We provide informed advice and services along the entire life cycle of products and health programmes - from upstream development to downstream programmes, including the surveillance of diseases within communities, policy making, and the forecasting of vaccine supply.

Filters

Region
Region
  • Africa
  • Americas
  • Europe
  • Oceania
Country
Country
  • Albania
  • Armenia
  • Bangladesh
  • Barbados
  • Belarus
  • Benin
  • Bosnia and Herzegovina
  • Brazil
  • Bulgaria
  • Cambodia
Focus Areas
Projects - Focus Areas
  • Access
  • Evaluation
  • Implementation
  • Policy & Strategy
Vaccine Preventable Diseases
Projects - Vaccine Preventable Diseases
  • Cholera
  • COVID-19
  • Diphtheria
  • Enteric Fever
  • Human Papillomavirus
  • Influenza
  • Japanese Encephalitis
  • Leishmaniasis
  • Measles-Rubella
  • Meningitis
Client
Projects - Clients
  • Asian Development Bank
  • Bill & Melinda Gates Foundation
  • Centers for Disease Control and Prevention (CDC)
  • Christian Medical College
  • Coalition for Epidemic Preparedness Innovation (CEPI)
  • EU Commission
  • Gavi, The Vaccine Alliance (Gavi)
  • Global Task Force on Cholera Control (GTFCC)
  • Inter American Development Bank
  • ISGlobal
Search
Sort By (Projects)
Image Credit: Vaxxas
  • Focus Project
2021 — 2023

Define use cases for micro-array patches for typhoid conjugate vaccines and assess their market feasibility

Develop and validate use cases for typhoid conjugate vaccine microarray patches (TCV-MAPs), determine which countries would use TCV-MAPs, and forecast potential demand as part of the development of the full vaccine value assessment.

Client
Gavi, The Vaccine Alliance (Gavi)
  • Focus Project
2021 — 2022

Develop an initial value assessment for measles-rubella microarray patches

Assessing public and private sector perspectives to identify solutions to roadblocks preventing the development and implementation of the measles-rubella microarray patch in low- and middle-income countries.

Client
UNICEF
  • Focus Project
2021 — 2022

Assess the factors enabling the rapid development and approval of COVID-19 vaccines

Identify and understand the factors that accelerated COVID-19 vaccine development and authorization timelines and develop actions to replicate these factors for vaccines needed in low- and middle-income countries.

Client
Wellcome Trust
Image Credit: Akiko Harayama
  • Focus Project
2020 — 2021

Define and prioritize research questions to support Ending Cholera – A Global Roadmap to 2030

Create a guide that focuses the allocation of resources (financial and human) towards answering the most pressing research questions that will have the most significant impact on our ability to control cholera.

Client
Wellcome Trust
Image Credit: Swarnavo Chakrabarti
  • Focus Project
2019 — 2020

Understanding the vaccine ecosystem: structure and challenges

Evaluation of the vaccine development ecosystem to identify areas for investment to support more efficient vaccine development for low-income countries and diseases with epidemic potential.

Client
Wellcome Trust
Image Credit: Unicef
  • Focus Project
2019 — 2020

Development of the Measles and Rubella Strategic Framework 2021-2030

Supporting development of the 10-year strategic framework for measles and rubella.

Client
Measles & Rubella Partnership
Image Credit: Akiko Harayama
  • Focus Project
2018 — 2018

Develop an investment case for a global roadmap to ending cholera

Develop a multi-sectorial investment case to support advocacy for fundraising to implement the Ending Cholera: A Global Roadmap to 2030 strategy.

Client
Global Task Force on Cholera Control (GTFCC), Bill & Melinda Gates Foundation
  • New Format
2021 — 2023

Support the WHO secretariat to the Strategic Advisory Group of Experts (SAGE)

Support the secretariat of the WHO SAGE on immunization to synthesize evidence on select topics and draft meeting reports to facilitate policy-making.

Client
World Health Organisation (WHO)
Image Credit: CDC
  • New Format
2019 — 2019

Improving access to meningitis vaccines

Support to the International Coordinating Group (ICG) for meningitis to improve access to vaccines for the international stockpile.

Client
World Health Organisation (WHO)
  • New Format
2018 — 2018

WHO position paper on pneumococcal conjugate vaccines for children under 5 years of age

Support WHO to draft and publish the position paper on pneumococcal conjugate vaccines in infants and children under 5 years of age.

Client
World Health Organisation (WHO)
2021 — Ongoing

Rapid Vaccine Manufacturing Diagnostic Study

MMGH is assisting the Inter-American Development Bank to prepare a rapid vaccine supply diagnostic study in support of work aimed at generating capacities in the countries that integrate PROSUR to produce vaccines for disease epidemics such as the COVID-19 pandemic. Through this project, MMGH is assessing existing vaccine manufacturing capacity in LAC region countries and regional demand and procurement mechanisms for COVID-19 and non-pandemic routine vaccines. A framework is also being developed to evaluate the optimal locations for investment to establish future vaccine manufacutring and fill and finish capabilities.

Client
Inter American Development Bank
2021 — Ongoing

Seasonal influenza vaccine value proposition: Development of a generic use case analytical framework and validation of use cases and country archetypes

MMGH is supporting the US CDC and WHO to validate preliminary use cases and country archetypes previously developed for seasonal influenza vaccines. MMGH is conducting staekholder surveys, interviews and workshops with global influenza experts to validate the use cases and country archetypes for seasonal influenza vaccines developed in the earlier project. These activities are also supporting the development of an analytical framework that is applicable to any influenza vaccine profile (e.g., next-generation and universal influenza vaccines). The project will help to support the full value of seasonal influenza vaccine assessment, including key market dynamics analayses and roadmaps and action plans for current and future seasonal influenza vaccine use.

Client
Centers for Disease Control and Prevention (CDC)
Image Credit: Gavi, the Vaccine Alliance
2020 — 2021

COVID-19 Support to Gavi, the Vaccine Alliance

MMGH supported Gavi, the Vaccine Alliance by documenting and synthesizing its key decisions related to the COVAX Facility and COVAX Advance Market Commitment (AMC). Activities include a desk review, key informant interviews, and thematic analysis. The conclusions from this work will serve to improve Gavi’s current learnings on the COVAX Facility and COVAX AMC design, governance, and operationalisation. Further information on the COVAX Facility and COVAX AMC can be found on the Gavi website.

Client
Gavi, The Vaccine Alliance (Gavi)
2019 — 2019

Human Papillomavirus (HPV) affordability analysis

MMGH supported the WHO Department of Immunisation and Biologicals (IVB) in defining a logical framework to assess the barriers to access human papillomavirus (HPV) vaccine in middle-income countries, with a focus on affordability. The project, performed in collaboration with the Clinton Health Access Initiative (CHAI), led to the identification of a subset of countries that can benefit from specific technical assistance related to affordability and access.

Client
World Health Organisation (WHO)
2019 — 2019

Redesign of the Eliminate Yellow Fever programme governance and work plan

MMGH supported the Eliminate Yellow Fever (EYE) Secretariat at WHO in streamlining programme governance and defining the general lines of action to serve as the foundation of a three-year multi-agency workplan. MMGH facilitated the interaction across the different partner agencies involved in the initiative and advised on the redesign of a streamlined governance structure. The streamlined governance structure should enable the initiative to have a more effective response to implementation challenges.

Client
World Health Organisation (WHO)
Image Credit: Yasmina Guerda
2018 — 2018

Development of operational guidelines on equity in immunisation

MMGH supported the WHO Regional Office for Europe in drafting operational guidelines for programme managers to measure inequities in immunisation, with a focus on understanding the root causes and implementing solutions to achieve equity in access to immunisation.

Client
World Health Organisation (WHO)
Image Credit: MMGH/Carsten Mantel
2018 — 2018

Middle Income Countries strategy for the European region

MMGH supported the WHO Regional Office for Europe in developing a strategic framework to address the challenges faced by the middle-income countries in the region. This framework informed the development of a detailed roadmap to implement the recommended actions.

Image Credit: MMGH/Carsten Mantel
2018 — 2018

Strategy for accelerated control of Japanese encephalitis in South East Asia

MMGH supported the WHO Regional Office for the Western Pacific in developing a guide for accelerating control of Japanese encephalitis (JE). The guide outlines regional targets, defines strategies and activities to accomplish these targets, and provides a framework for countries to develop national plans tailored to their situation. MMGH collaborated with the WHO Regional Office, country representatives and global experts to facilitate a meeting, draft the guidance and work towards an endorsed and funded strategy for JE control in the region.

Client
World Health Organisation (WHO)
Image Credit: MMGH/Carsten Mantel
2017 — 2017

Maternal Immunisation and Antenatal Care Situational Analysis (MIACSA)

MMGH supported the WHO in conducting a Bill & Melinda Gates Foundation supported project that investigated and analysed the status of maternal immunisation delivery strategies in low and middle-income countries. This included developing a typology of health systems in terms of how they deliver vaccines to pregnant women, and exploring approaches to improve country readiness for delivering new maternal vaccines, such as those against Respiratory Syncytial Virus and Group B Streptococcus.

Client
World Health Organisation (WHO)
2017 — 2017

Development of the WHO’s typhoid vaccines position paper

MMGH supported the WHO Initiative for Vaccine Research (IVR) in facilitating a Strategic Advisory Group of Experts on Immunisation (SAGE) Working Group review of the scientific evidence and programmematic considerations supporting use of typhoid vaccines, with a focus on conjugate vaccines. The resulting vaccine recommendations were endorsed by the WHO SAGE in October 2017 and published as a WHO Position Paper.

Client
World Health Organisation (WHO)
2017 — 2017

Immunisation Practices Advisory Committee (IPAC) ToR revision

MMGH supported the WHO Immunisation Practices Advisory Committee (IPAC) Secretariat in revising the committee’s Terms of Reference (ToR). Based on information collected by MMGH during a series of in-depth stakeholder interviews and discussions, the functions of the committee were aligned with the new WHO structure and workplan as well as with those of other WHO global immunisation advisory groups.

Client
World Health Organisation (WHO)